Import Safety Rules Should Not Hinder Legitimate Generic Drug Markets
Appearing in IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY (Cary Coglianese, Adam Finkel, & David Zaring, eds., 2009) (The University of Pennsylvania Press)
Trade agreement negotiations are routinely cloaked in secrecy, a model that may have suited the Eighteenth Century, but has no place in modern democracies. Transparency deficits have led to capture by powerful industries, sometimes to the detriment of public health. This is a standard account of the WTO TRIPS Agreement, but the pattern is being repeated, in a new regime, in the Anti-Counterfeiting Trade Agreement (ACTA) and related efforts. In the context of pharmaceuticals, ACTA should be limited to deliberate trademark violations and should not be expanded to encompass other intellectual property rights such as patent infringement. Recent seizures of generic medicines by Dutch authorities highlight the danger to legitimate and valuable global generic drug markets from overzealous enforcement of border control regimes.
Keywords: counterfeit, drug, pharmaceutical, Anti-Counterfeit Trade Agreement, ACTA, IMPACT
SSRN Accepted Paper Series
Size: 180 KB
Adobe Acrobat Reader v3.01 or greater is required to view this paper.
Kevin Outterson, Appearing in IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY (Cary Coglianese, Adam Finkel, & David Zaring, eds., 2009) (The University of Pennsylvania Press)
Kevin Outterson Contact Information
Email address: email@example.com
Office Phone: (617) 353-3135